New Delhi: Shares of Cipla jumped around 2 percent intraday on Tuesday after it announced a commercial collaboration with UK-based S&D Pharma to enter Czech Republic and Slovakia.
At 10:53 am, the stock surged 0.87 per cent to Rs 568.30.
The agreement involved Cipla driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head.
S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.
Cipla will also launch its respiratory inhaler Salmeterol-Fluticasone fixed combination in these markets under the name Fullhale, once regulatory and reimbursement approvals are in place.
